Daily Disruptor: $ASPI, Three Revenue Lines, One Morning

The 30 second version

• ASP Isotopes enriches critical isotopes for quantum computing, nuclear medicine, and nuclear energy, and it is the only western supplier of enriched Silicon-28 in the world.
• Revenue went from $0.5M in all of 2024 to $5.7M in 2025, and Q1 2026 alone brought in $4.18M, before any of the high value isotope or helium lines had started commercial shipments.
• Catalyst is today: Q2 2026 earnings come out pre market August 14, and a shareholder letter from August 5 previewed PET Labs up more than 50% organically in the first half, with helium production at Renergen targeted before September 30.
• Main risk: an active class action over HALEU uranium enrichment claims that survived a motion to dismiss, plus a history of heavy share issuance that has diluted shareholders.
• Market cap approximately $640 to $800 million; coverage thin; the class action overhang is exactly what keeps institutional money on the sideline while the real business scales.

In Q1 2026, ASP Isotopes brought in $4.18 million in revenue, 280% more than the same quarter a year earlier. The entire company generated just $0.5 million in product revenue through all of 2024. Something changed. That something is worth understanding before today’s Q2 print hits.

The stock trades around $7, down sharply from its 52-week high of $14.49, dragged by a securities class action and a series of equipment delays that pushed several commercial shipment dates from Q2 into the second half of 2026. The market read “delay” as “failure.” What the filings actually show is a company that replaced faulty valves and compressors from an OEM supplier, restarted its Silicon-28 facility, got it running for over three weeks at target enrichment levels, and then told shareholders it expects initial product shipments in the second half of this year. That is a different sentence.

What just happened

On August 5, nine days before today’s earnings release, management put out a shareholder letter. The letter was not hedged. PET Labs, the company’s radiopharmacies division, is on track to deliver approximately $14 million in full year 2026 revenue, up from $6 million in 2025. Organic growth in the first half of 2026 was more than 50% above the same period last year. That is the business no one talks about when they debate whether ASPI’s isotope enrichment technology is real.

Then there is Renergen, the South African helium and LNG subsidiary ASPI acquired in January 2026. Drilling for Phase 1 of the Virginia Gas Project was completed four months ahead of schedule. Management has committed to commencing helium production before September 30, 2026, six weeks from today. At nameplate capacity, annualized helium and LNG revenues from Phase 1 alone are projected at approximately $27 million, supported by an offtake contract at an initial base price above $600 per thousand cubic feet. With roughly 50% of global helium supply currently offline for various geopolitical reasons, the timing is deliberate. The company also secured an Asian industrial gases buyer for about 15% of Phase 1 helium capacity.

Silicon-28 and Ytterbium-176 are the third and fourth lines. ASPI signed three commercial purchase agreements for enriched Si-28 with a major US semiconductor company, a large industrial gases company, and a third US buyer. The use case is quantum computing and next generation semiconductors, and ASPI describes itself as the world’s only western supplier. First shipments are expected in the second half of 2026. The Yb-176 facility, which feeds into Lutetium-177 production for cancer treatment, was damaged by a power surge in 2025 but is back in the final stages of commercial production. Every one of these revenue lines starts in the window from today through the end of this quarter.

The business

ASP Isotopes uses its proprietary Aerodynamic Separation Process to enrich isotopes in Pretoria, South Africa. The approach differs from gaseous diffusion or centrifuge methods and is designed for low volume, high value materials where the global supply chain is either thin or Chinese dominated. Silicon-28, enriched to specific isotopic purity levels, enables more stable qubits in quantum computers and dramatically reduces phonon scattering in next generation semiconductors for data centers. The company holds three signed purchase agreements from customers who visited its facility in the second half of 2025 and validated the enrichment levels independently.

What most readers will miss is the radiopharmacy business. ASPI has been quietly acquiring PET scanning labs in Florida and South Carolina while the isotope enrichment story dominates headlines. PET Labs is already generating real revenue, is on a verified growth trajectory, and needs none of the enrichment technology to work. It is the business that funds the wait. One filing detail worth noting: the 2025 net loss attributable to shareholders was $175 million, but the vast majority of that reflects non cash items tied to the Renergen acquisition structure and capital raises, not cash burned in the lab. Cash operating burn in Q1 2026 was just under $25 million.

The numbers

Revenue trajectory: $0.5M in 2024, $5.7M in 2025, $4.18M in Q1 2026 alone. PET Labs is guiding $14M for the full year 2026, more than double the 2025 base. If helium reaches nameplate capacity by the end of Q3 as guided, annualized contributions of $27M begin flowing. The operating loss narrowed from $8.45M in Q1 2025 to $6.88M in Q1 2026, the first sign of loss moderation as revenue scales faster than cost. Cash and short term investments at the end of Q1 2026 stood at just over $290 million, against quarterly cash operating burn of roughly $25 million. That is more than two years of runway at current burn, with new revenue lines about to reduce the net outflow.

There is no formal sell side consensus for ASPI. Canaccord had a price target in the $11 to $13 range at last count. The stock is currently around $7. The gap between those numbers is not the thesis on its own, but it tells you the coverage count is thin enough that one or two upgrade events could move the float materially. Management has given specific 2026 guidance: $14M from PET Labs, $27M annualized from Phase 1 helium at nameplate, and first commercial isotope shipments in 2H 2026. The Q2 print today either confirms the trajectory or creates a bigger entry point.

Why the market has not caught up

Three things are keeping institutional money away from this name. First, the class action. A securities fraud complaint alleging that ASPI misled investors about its HALEU uranium enrichment technology, specifically that the company had never tested its Quantum Enrichment process on actual uranium, survived a motion to dismiss in December 2025. That headline alone pulls any ESG sensitive or compliance constrained fund manager off the name, regardless of what the radiopharmacy and helium businesses are doing. Second, the equipment delays. When Si-28 shipments moved from Q2 to 2H 2026, the stock fell, and most analysts noted the miss without noting that the cause was an OEM compressor failure, not a technology failure. Third, the optics of heavy share issuance. ASPI raised over $345 million in new capital during 2025, and the dilution is visible and uncomfortable to model.

What the filings show is a company that has crossed the line from concept to cash flow in its radiopharmacy segment, is weeks away from helium production, has three signed purchase contracts for an isotope with no western competitor, and is sitting on nearly $300 million in liquidity. The litigation concerns a specific subset of the business, not the segments that are now generating revenue. The market has priced the whole story at the litigation discount.

What breaks it

The class action is the clearest single risk. If the HALEU uranium claims proceed to trial and the evidence supports the allegations that management overstated technology readiness to raise capital, the reputational damage extends well beyond the HALEU segment and compounds the dilution problem. Helium production delays beyond September 30 would also reset expectations hard, given that management has made the timing specific and public. The company must raise capital again eventually, with 126 million shares outstanding and a burn rate still significant, another offering in 2027 seems likely, and at current prices that would be dilutive.

What we are watching

• August 14, 2026 (today, pre market): Q2 2026 revenue and loss figures. Watch whether PET Labs is tracking to the $14M full year guide and whether management confirms any initial helium or isotope revenue in Q2.
• September 8, 2026: ASPI Capital Markets Day in London, coinciding with the World Nuclear Association Symposium. This is where ASPI is most likely to present commercial isotope milestones alongside the nuclear fuel partnership with TerraPower.
• September 30, 2026: Management’s committed date for commencing helium production at Renergen’s Virginia Gas Project. A miss here would be meaningful; a hit with first revenue would reframe the entire story.

Not financial advice.

References

1. ASP Isotopes Inc. Form 8-K. Business Update, First Commercial Shipments Expected Across Multiple Isotopes in 2026. Published April 13, 2026. Accessed August 14, 2026. https://www.sec.gov/Archives/edgar/data/1921865/000147793226002140/aspi_ex991.htm
2. ASP Isotopes Inc. Form 8-K. Engineering Enhancements to Silicon-28 Enrichment Facility. Published May 26, 2026. Accessed August 14, 2026. https://ir.aspisotopes.com/news-events/press-releases/detail/107/asp-isotopes-implements-engineering-enhancements-to
3. ASP Isotopes Inc. Form 8-K. Shareholder Letter, Q2 2026 Business Update. Published August 5, 2026. Accessed August 14, 2026. https://ir.aspisotopes.com/news-events/press-releases/detail/114/aspisotopes-issues-letter-to-shareholders
4. ASP Isotopes Inc. Form 10-Q for the quarterly period ended March 31, 2026. US Securities and Exchange Commission. Published May 2026. Accessed August 14, 2026. https://www.sec.gov/Archives/edgar/data/0001921865/000119312526237916/aspi-ex99_1.htm
5. Grabar Law Office. ASP Isotopes Inc. (ASPI) Class Action Survives Motion to Dismiss. Published March 25, 2026. Accessed August 14, 2026. https://www.newsfilecorp.com/release/290051/Grabar-Law-Office-Investigates-Claims-on-Behalf-of-Investors-of-ASP-Isotopes-Inc.-ASPI-as-Class-Action-Survives-Motion-to-Dismiss
6. MarketBeat. ASP Isotopes (ASPI) Projected to Announce Quarterly Earnings on Friday. Published August 7, 2026. Accessed August 14, 2026. https://www.marketbeat.com/instant-alerts/asp-isotopes-aspi-projected-to-announce-quarterly-earnings-on-friday-2026-08-07/
7. Investing.com. ASP Isotopes Projects $14M Revenue from PET Labs in 2026. Published August 5, 2026. Accessed August 14, 2026. https://ca.investing.com/news/stock-market-news/asp-isotopes-projects-14m-revenue-from-pet-labs-in-2026-93CH-4773870
8. StockTitan. ASP Isotopes Letter Forecasts $14M PET Labs Revenue. Published August 5, 2026. Accessed August 14, 2026. https://www.stocktitan.net/news/ASPI/asp-isotopes-issues-letter-to-f